Please login to the form below

Not currently logged in
Email:
Password:

tenofovir disoproxil

This page shows the latest tenofovir disoproxil news and features for those working in and with pharma, biotech and healthcare.

Gilead set to acquire hepatitis specialist MYR for €1.15bn

Gilead set to acquire hepatitis specialist MYR for €1.15bn

In the phase 2 MYR202 study, 54 of 90 patients treated with Hepcludex and tenofovir disoproxil fumarate (TDF) had at least a 2 log10 HDV RNA decline or undetectable HDV RNA

Latest news

  • NHS England will make PrEP for HIV available in April NHS England will make PrEP for HIV available in April

    The PrEP Impact Trial is using Mylan's generic version of Gilead Sciences’ antiretroviral therapy Truvada (emtricitabine/tenofovir disoproxil) but is due to come to an end in October.

  • Gilead builds case for Descovy PrEP after FDA approval Gilead builds case for Descovy PrEP after FDA approval

    Descovy (emtricitabine/tenofovir alafenamide) claimed its  FDA approval for PrEP last week – becoming only the second drug for this use since Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) got a green

  • Gilead claims FDA okay for Descovy as second PrEP option Gilead claims FDA okay for Descovy as second PrEP option

    Descovy (emtricitabine and tenofovir alafenamide) has been cleared for adolescents and adults who are at risk of HIV infection because they have sex with an HIV-positive partner. ... In a statement, the FDA said that Descovy’s efficacy in preventing

  • MSD claims EU approval for two HIV products MSD claims EU approval for two HIV products

    The pair – non-nucleoside reverse transcriptase inhibitor (NNRTI) Pifeltro (doravirine) and single-tablet combination Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate) – are a much-needed bolster for Merck’s HIV portfolio,

  • ViiV chalks up another win for two-drug HIV regimen ViiV chalks up another win for two-drug HIV regimen

    effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... Gilead’s new fixed-dose Biktarvy

More from news
Approximately 5 fully matching, plus 39 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics